Epigenetic Deregulation of GATA3 in Neuroblastoma is Associated with Increased GATA3 Protein Expression and with Poor Outcomes

Overview

Journal Sci Rep

Specialty Science

Date 2019 Dec 14

PMID 31831790

Citations 12

Authors

Bader Almutairi

Jessica Charlet

Anthony R Dallosso

Marianna Szemes

Heather C Etchevers

Karim T A Malik

Keith W Brown

Affiliations

Soon will be listed here.

Abstract

To discover epigenetic changes that may underly neuroblastoma pathogenesis, we identified differentially methylated genes in neuroblastoma cells compared to neural crest cells, the presumptive precursors cells for neuroblastoma, by using genome-wide DNA methylation analysis. We previously described genes that were hypermethylated in neuroblastoma; in this paper we report on 67 hypomethylated genes, which were filtered to select genes that showed transcriptional over-expression and an association with poor prognosis in neuroblastoma, highlighting GATA3 for detailed studies. Specific methylation assays confirmed the hypomethylation of GATA3 in neuroblastoma, which correlated with high expression at both the RNA and protein level. Demethylation with azacytidine in cultured sympathetic ganglia cells led to increased GATA3 expression, suggesting a mechanistic link between GATA3 expression and DNA methylation. Neuroblastomas that had completely absent GATA3 methylation and/or very high levels of protein expression, were associated with poor prognosis. Knock-down of GATA3 in neuroblastoma cells lines inhibited cell proliferation and increased apoptosis but had no effect on cellular differentiation. These results identify GATA3 as an epigenetically regulated component of the neuroblastoma transcriptional control network, that is essential for neuroblastoma proliferation. This suggests that the GATA3 transcriptional network is a promising target for novel neuroblastoma therapies.

Citing Articles

GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis.

Plage H, Frericks A, Hofbauer S, Furlano K, Weinberger S, Rossner F BMC Urol. 2025; 25(1):37.

PMID: 39979991 PMC: 11841250. DOI: 10.1186/s12894-025-01704-y.

Aryl hydrocarbon receptor is a tumor promoter in -amplified neuroblastoma cells through suppression of differentiation.

Chaudhry K, Jacobi J, Gillard B, Karasik E, Martin J, da Silva Fernandes T iScience. 2023; 26(11):108303.

PMID: 38026169 PMC: 10654598. DOI: 10.1016/j.isci.2023.108303.

Is Depleted in Colon Cancer Patients and Its Expression Is Induced by 5-aza-2'-Deoxycytidine In Vitro.

Almutairi B, Almutairi M, Alrefaei A, Alkahtani S, Alarifi S Medicina (Kaunas). 2023; 59(5).

PMID: 37241227 PMC: 10220775. DOI: 10.3390/medicina59050996.

Characterization of m6A-related lncRNA signature in neuroblastoma.

Li L, Chen S, Li J, Rong G, Yang J, Li Y Front Pediatr. 2022; 10:927885.

PMID: 36324814 PMC: 9618704. DOI: 10.3389/fped.2022.927885.

Cigarette Smoke Regulates the Expression of EYA4 via Alternation of DNA Methylation Status.

Almutairi B, Almutairi M, Alrefaei A, Ali D, Alkahtani S, Alarifi S Biomed Res Int. 2022; 2022:5032172.

PMID: 35607307 PMC: 9124125. DOI: 10.1155/2022/5032172.

References

Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V . Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017; 49(9):1408-1413. DOI: 10.1038/ng.3921. View

van Limpt V, Chan A, Schramm A, Eggert A, Versteeg R . Phox2B mutations and the Delta-Notch pathway in neuroblastoma. Cancer Lett. 2005; 228(1-2):59-63. DOI: 10.1016/j.canlet.2005.02.050. View

Valentijn L, Koster J, Zwijnenburg D, Hasselt N, van Sluis P, Volckmann R . TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. Nat Genet. 2015; 47(12):1411-4. DOI: 10.1038/ng.3438. View

Charlet J, Szemes M, Malik K, Brown K . MYCN is recruited to the RASSF1A promoter but is not critical for DNA hypermethylation in neuroblastoma. Mol Carcinog. 2013; 53(5):413-20. DOI: 10.1002/mc.21994. View

Buckley P, Das S, Bryan K, Watters K, Alcock L, Koster J . Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer. 2010; 128(10):2296-305. DOI: 10.1002/ijc.25584. View

Simoes-Costa M, Bronner M . Insights into neural crest development and evolution from genomic analysis. Genome Res. 2013; 23(7):1069-80. PMC: 3698500. DOI: 10.1101/gr.157586.113. View

Wiles A, Karrs J, Pitt S, Almenara J, Powers C, Smith S . GATA3 is a reliable marker for neuroblastoma in limited samples, including FNA Cell Blocks, core biopsies, and touch imprints. Cancer Cytopathol. 2017; 125(12):940-946. DOI: 10.1002/cncy.21927. View

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Henrich K, Bender S, Saadati M, Dreidax D, Gartlgruber M, Shao C . Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. Cancer Res. 2016; 76(18):5523-37. DOI: 10.1158/0008-5472.CAN-15-2507. View

10.

Jiang M, Stanke J, Lahti J . The connections between neural crest development and neuroblastoma. Curr Top Dev Biol. 2011; 94:77-127. PMC: 3633592. DOI: 10.1016/B978-0-12-380916-2.00004-8. View

11.

Baylin S, Jones P . Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016; 8(9). PMC: 5008069. DOI: 10.1101/cshperspect.a019505. View

12.

Fransecky L, Neumann M, Heesch S, Schlee C, Ortiz-Tanchez J, Heller S . Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL. J Hematol Oncol. 2016; 9(1):95. PMC: 5034449. DOI: 10.1186/s13045-016-0324-8. View

13.

van Groningen T, Koster J, Valentijn L, Zwijnenburg D, Akogul N, Hasselt N . Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017; 49(8):1261-1266. DOI: 10.1038/ng.3899. View

14.

Yang Q, Kiernan C, Tian Y, Salwen H, Chlenski A, Brumback B . Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res. 2007; 13(11):3191-7. DOI: 10.1158/1078-0432.CCR-06-2846. View

15.

Peng H, Ke X, Hu R, Yang L, Cui H, Wei Y . Essential role of GATA3 in regulation of differentiation and cell proliferation in SK-N-SH neuroblastoma cells. Mol Med Rep. 2014; 11(2):881-6. PMC: 4262502. DOI: 10.3892/mmr.2014.2809. View

16.

Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen H . Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin Cancer Res. 2004; 10(24):8493-500. DOI: 10.1158/1078-0432.CCR-04-1331. View

17.

Pugh T, Morozova O, Attiyeh E, Asgharzadeh S, Wei J, Auclair D . The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013; 45(3):279-84. PMC: 3682833. DOI: 10.1038/ng.2529. View

18.

Sausen M, Leary R, Jones S, Wu J, Reynolds C, Liu X . Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet. 2012; 45(1):12-7. PMC: 3557959. DOI: 10.1038/ng.2493. View

19.

Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E . Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015; 47(8):872-7. DOI: 10.1038/ng.3349. View

20.

Tsarovina K, Pattyn A, Stubbusch J, Muller F, Wees J, Schneider C . Essential role of Gata transcription factors in sympathetic neuron development. Development. 2004; 131(19):4775-86. DOI: 10.1242/dev.01370. View